glp 1 care credit Oral GLP-1 Orforglipron Is Approved for Obesity Use CareCredit for the Mayo
Description
Thank you for all you do
We recommend conducting this review between two and four weeks after the patient starts taking the GLP-1RA
While Novo Nordisk provides warning labels about common side effects of Wegovy and their other semaglutide medications, their labels may not provide adequate warning about severe health risks such as stomach paralysis, intestinal blockages, or bowel obstruction
Serious side effects can occur with semaglutide
Greco EV, Russo G, Giandalia A, et al
Lab work may be required
